CRL and IQV Related Headlines
Go Back- Morgan Stanley favors Charles River Over IQVIA in CRO sector reset
- Morgan Stanley Downgrades IQVIA Holdings (IQV) to Equalweight
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- Jefferies finds AI drives up to 50% cost cuts in drug development
- FDA issues draft guidance to reduce animal testing for cancer drugs
- Jefferies backs IQVIA and Charles River, cuts ICON on customer losses
